ABSTRACT
The present paper describes simple, rapid, reproducible, accurate and precise stability indicating HPLC method developed for quantitative simultaneous estimation of metoprolol succinate and olmesartan medoxomil in bulk and combined pharmaceutical dosage form. A chromatographic separation of both drugs was achieved with Chromasil 250 x 4.6 mm, i.d 5 µm C-18 column using methanol:0.05% v/v O-phosphoric acid in water (50:50 v/v) at the flow rate of 1ml/min. The measurements were made at 228.0 nm as detector wavelength. The described method showed excellent linearity over a range of 5-80 µg/ml for metoprolol succinate and 5-70 µg/ml for olmesartan medoxomil. The coefficient of correlation for metoprolol succinate and olmesartan medoxomil was found to be 0.9990 and 0.9993 respectively. The retention time for metoprolol succinate and olmesartan medoxomil was found to be 3.485 min and 7.085 min, respectively. The tailing factor for metoprolol succinate and olmesartan medoxomil was found to be 1.02 and 1.13 respectively. Both drugs and their combination drug product were found to be stable in neutral, thermal, oxidative and photolytic stress conditions but mild degradation was observed in acidic and alkaline conditions.

Keywords: Metoprolol succinate; Olmesartan medoxomil; HPLC method validation; Stability-indicating method; ICH guidelines.

INTRODUCTION
Chemically, Metoprolol succinate (MET) (Fig.1) is (±)-1-(isopropylamino-3-[4-[(2-methoxyethyl)phenoxy]propan-2-ol. It is used as an antianginal and antihypertensive. The official methods of assay like Potentiometric and HPLC are reported for MET. Chemically, Olmesartan medoxomil (OLM) (Fig. 1) is 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[(22-(1H-tetrazol-5-yl)[1,12-biphenyl]-4-yl)methyl]-1H-imidazole-5-carboxylic acid (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester. It is selective angiotensin II receptor antagonist and used as an antihypertensive. OLM lowers blood pressure and increases the supply of blood and oxygen to the heart. OLM and MET is a combination of medicines used to treat high blood pressure (hypertension). Literature survey revealed that various methods like UV spectrophotometric, HPLC and GC-MS for the estimation of metoprolol succinate as single and HPLC in combination with other antihypertensive agents are reported. The methods such as UV spectrophotometric, estimation of OLM in plasma, urine and tablet by HPLC and LC-MS detection for olmesartan medoxomil as single and HPLC method in combination with other drugs are

Fig. 1: Chemical structure of MET and OLM

*Correspondence: sonalimahaparale@gmail.com Mob + 91 98506 53148
RESULTS
Optimization of the chromatographic conditions:
To develop a stability-indicating method, different stationary phases like C18, CN, different mobile phases containing buffers like phosphate, ammonium acetate, with different pH (3-7), and organic modifier (acetonitrile) were used. The aim of the present study accordingly was to establish inherent stability of metoprolol succinate and olmesartan medoxomil in combined tablet dosage form through stress studies under ICH recommended test conditions and to develop and validate stability indicating HPLC method.

EXPERIMENTAL
Chemicals and reagents
Reference standards of metoprolol succinate and olmesartan medoxomil were procured from Lupin Research Park, Pune and Emcure Pharmaceuticals Ltd., Pune respectively. Methanol (HPLC grade) was obtained from Qualigen Laboratories Pvt. Ltd., Mumbai. Analytical grade of hydrochloric acid (HCl), sodium hydroxide (NaOH), o-phosphoric acid and hydrogen peroxide were obtained from Merck Ltd., Mumbai. The tablets containing metoprolol succinate (25 mg) and olmesartan medoxomil (20 mg) were procured from local market.

Instrument
The chromatographic system used was an Agilent 1120 series, which comprised a degasser, gradient pump and photodiode array detector. The system was controlled through Ezchrome software using Chromasil C18 (4.6 x 250mm, 5 µm) column maintained at 25°C temperature.

Chromatographic conditions
The separation was achieved using a mobile phase consisting methanol:0.05% v/v o-phosphoric acid in water (50:50 v/v) at a flow rate of 1.0 ml/min and the eluent was monitored using PDA detector at 228.0 nm. The mobile phase was kept in ultrasonicator for 30 min and filtered through a 0.45-µm nylon membrane filter. The column was maintained at 25°C temperature and injection volume of 20 µl was used. The peak homogeneity was expressed in terms of peak purity and was obtained directly from software.

Standard stock solutions
The stock solution (100 µg/ml) of MET and OLM were prepared separately by dissolving accurately 10 mg of each drug in 100 ml methanol HPLC grade in 100 ml volumetric flask.

Calibration curve
Appropriate aliquots of standard stock solutions of MET and OLM were diluted with mobile phase to obtain concentrations in the range of 5, 10, 20, 30, 40, 50, 60, 70 and 80 µg/ml of MET and 5, 10, 20, 30, 40, 50, 60 and 70 µg/ml of OLM respectively. The linearity of MET (Fig. 2) and OLM (Fig. 3) was found to be in the concentration ranges of 5-80 µg/ml and 5-70 µg/ml, respectively, at their respective maxima. The coefficients of correlation were found to be 0.9990 for MET and 0.9993 for OLM. The mixed standard solution containing 50 µg/ml of MET and 40 µg/ml of OLM was prepared from each standard stock solution and injected into HPLC system.
Metoprolol and Olmesartan determination

volume 20 l. It was found to ideally resolve the peaks of MET (Rt 3.485 min) and OLM (Rt 7.085 min) (Fig.4). Resolution (Rs) between MET and OLM was found to be 10.28. ICH guidelines recommend 10-20 % degradation for establishing stability indicating nature of the assay method.

Resolution (Rs) = \( \frac{t_2 - t_1}{w_1 + w_2} \)

\( t_1, t_2 \) are retention time of MET and OLM respectively, \( w_1, w_2 \) are width of peaks for MET and OLM respectively, Rs = 7.085 - 3.485 / 0.15 + 0.2

Rs = 3.6 / 0.35 = 10.28

Analysis of tablet formulation:

Twenty tablets of Rasotan Beta 25 (Emcure Pharma) each containing 25 mg of metoprolol succinate and 20 mg of olmesartan medoxomil were weighed and crushed in glass mortar to obtain fine powder. The powder sample equivalent to 25 mg of MET and 20 mg of OLM was transferred into a 100 ml volumetric flask and dissolved in 50 ml methanol HPLC grade. The flask was kept in an ultrasonic bath for 20 min. The volume was adjusted to 100 ml with methanol HPLC grade. The solution was filtered through 0.2 µm nylon membrane filter. From this stock solution, 2 ml solution was pipetted out and transferred into a 10 ml volumetric flask and made volume up to the mark with mobile phase to get the concentration 50 µg/ml of MET and 40 µg/ml of OLM. Then the solution was injected into system (Fig. 5).

<table>
<thead>
<tr>
<th>Tablet contents</th>
<th>Label amount (mg/ml)</th>
<th>Mean label content (%)</th>
<th>% Label</th>
<th>Standard deviation</th>
<th>Standard error</th>
</tr>
</thead>
<tbody>
<tr>
<td>MET</td>
<td>25</td>
<td>19.86</td>
<td>0.15</td>
<td>0.005</td>
<td>0.1898</td>
</tr>
<tr>
<td>OLM</td>
<td>20</td>
<td>40.90</td>
<td>0.20</td>
<td>0.035</td>
<td>0.2363</td>
</tr>
</tbody>
</table>

*Average of six readings

MET and OLM denotes metoprolol succinate and olmesartan medoxomil respectively

Procedure for forced degradation study of drug substances

Forced degradation of each drug substances and the drug product was carried out under acid, base, neutral, oxidative, thermolytic and photolytic stress conditions.

Acidic degradation

The accurate quantity of 2.5 mg MET and 2.5 mg OLM was weighed and transferred to 25 ml volumetric flask separately; 10 ml of 0.1 N HCl was added into each flask separately and the flask was kept for 2 hrs at room temperature. Then it was neutralized with 0.1 N NaOH and solution was sonicated for 30 min with intermittent shaking in ultrasonicator. Then the volume was made up with methanol HPLC grade and each solution was filtered through 0.2 µm membrane filter. From the filtered stock solutions, 5 ml of MET and 4 ml of OLM was pipetted out separately and transferred into a 10 ml volumetric flask and diluted to volume with mobile phase to obtain final concentration of 50 µg/ml of MET and 40 µg/ml OLM. Then the solution was injected into system (Fig. 6).

Alkali degradation

Alkali degradation was carried out by adding 10 ml of 1 N NaOH and the mixture was refluxed for 30 min at 60°C. Then it was neutralized with 1 N HCl and the solution was sonicated for 30 min with intermittent shaking in ultrasonicator (Fig. 7).
Metoprolol and Olmesartan determination

Neutral degradation
10.0 ml distilled water was added to each stock solution of MET and OLM separately. Both solutions were refluxed at 60°C for 2 hrs and cooled at room temperature (Fig. 8).

Oxidative degradation
Oxidative stress degradation of MET and OLM was conducted with 30% H₂O₂ for 2 hrs at 60°C in a water bath (Fig. 9).

Thermal degradation
About 100 mg of drug substances were placed in a controlled temperature oven at 80°C for 48 hrs. (Fig.10)

Photodegradation (UV light)
Photodegradation was performed by spreading the drug substance in petri dish as thin film and kept in a photostability chamber equipped with ultraviolet light with energy of not less than 200 watt hours/square meter (Fig. 11).

Photodegradation (fluorescence light)
Photodegradation was performed by exposing the drug substance in photostability chamber equipped with fluorescence light illumination not less than 1.2 million lux hours. Sample was weighed, dissolved and diluted to obtain final concentration and injected into system. (Fig. 12)

The results of forced degradation study of standard the proposed method are shown in Table 2.

### Table 2: Results of forced degradation study

<table>
<thead>
<tr>
<th>Stress condition</th>
<th>Degradation (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>MET</td>
<td>OLM</td>
</tr>
<tr>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>Acidic + Oxidative</td>
<td>7.12</td>
</tr>
<tr>
<td>Basic + Oxidative</td>
<td>0.25</td>
</tr>
<tr>
<td>Neutral + Oxidative</td>
<td>1.20</td>
</tr>
<tr>
<td>Photostability</td>
<td>0.20</td>
</tr>
<tr>
<td>Thermal</td>
<td>0.00</td>
</tr>
</tbody>
</table>

MET and OLM denotes metoprolol succinate and olmesartan medoxomil respectively.
Metoprolol and Olmesartan determination
Method Validation
Linearity
Linearity for MET and OLM was selected at 5-80 ìg/ml and 5-70 ìg/ml. The correlation coefficients were selected at 0.9990 and 0.9993 for MET and OLM, respectively. The results are shown in Table 3.

Table 3: System Suitability Parameters

<table>
<thead>
<tr>
<th>Parameter</th>
<th>MET</th>
<th>OLM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Linear range* (ìg/ml)</td>
<td>5-90</td>
<td>5-70</td>
</tr>
<tr>
<td>Correlation coefficient</td>
<td>0.9990</td>
<td>0.9993</td>
</tr>
<tr>
<td>Slope</td>
<td>139.65</td>
<td>207.83</td>
</tr>
<tr>
<td>Limit of detection (ìg/ml)</td>
<td>0.020</td>
<td>0.024</td>
</tr>
<tr>
<td>Limit of quantitation (ìg/ml)</td>
<td>0.060</td>
<td>0.073</td>
</tr>
<tr>
<td>Retention time* (min)</td>
<td>3.408</td>
<td>7.085</td>
</tr>
<tr>
<td>Tailing factor</td>
<td>1.024</td>
<td>1.134</td>
</tr>
<tr>
<td>Theoretical plates*</td>
<td>8246</td>
<td>6452</td>
</tr>
</tbody>
</table>

*Average of six readings
MET and OLM denotes metoprolol succinate and olmesartan medoxomil respectively.

Specificity
Photodiode array detection was used as an evidence of the specificity of the method and to evaluate the homogeneity of the drug peak. The peak purity values for analyte peaks, MET and OLM, were in the range of 999–1000 for drug substance and in the range of 998–1000 for tablets, indicating homogeneous peaks and thus establishing the specificity of assay method.

Determination of Limits of Quantification and Detection
The limit of detection (LOD) and limit of quantitation (LOQ) for MET and OLM were determined at a signal-to-noise ratio of 3:1 and 10:1 respectively, by injecting a series of dilute solutions with known concentration. The LODs for MET and OLM were 0.020 ìg/ml and 0.024 ìg/ml, respectively and the LOQs were 0.060 and 0.073 ìg/ml, respectively (Table 3).

Precision (repeatability)
The precision of the method was studied by determining the concentrations of each drug in the tablets six times. The results of the precision study indicate that the method is reliable (%RSD<2).

Accuracy (recovery test)
Accuracy of the method was studied by recovery experiments. The recovery was performed at three levels, 80 %, 100 %, and 120 % of the label claim of the tablet (25 mg of MET and 20 mg of OLM). The results are shown in Table 4.

Robustness
The robustness of a method is the ability of method to remain unaffected by small changes in parameters like mobile phase composition, flow rate, pH of mobile phase and temperature etc.

DISCUSSION
The results obtained by the stress degradation conditions of both drugs showed that validated stability-indicating RP-HPLC method is specific, simple, rapid, reproducible, accurate and precise method developed for the quantitative simultaneous estimation of metoprolol succinate and olmesartan medoxomil in combined tablet dosage form. In the future, this method may be applied for routine analysis of both the drugs in API, formulations, dissolution studies, bioavailability and pharmacokinetic studies.

ACKNOWLEDGMENTS
The authors are thankful to the Principal, Padm. Dr. D. Y. Patil College of Pharmacy, Pune for providing excellent research facilities and Emcure Pharmaceuticals Ltd., Pune and Lupin Research Park, Pune for providing the gift sample of olmesartan medoxomil and metoprolol succinate respectively.

REFERENCES


